PL2010190T3 - Formulacje roztworu farmaceutycznego do inhalatorów ciśnieniowych z dozownikiem - Google Patents

Formulacje roztworu farmaceutycznego do inhalatorów ciśnieniowych z dozownikiem

Info

Publication number
PL2010190T3
PL2010190T3 PL07724357T PL07724357T PL2010190T3 PL 2010190 T3 PL2010190 T3 PL 2010190T3 PL 07724357 T PL07724357 T PL 07724357T PL 07724357 T PL07724357 T PL 07724357T PL 2010190 T3 PL2010190 T3 PL 2010190T3
Authority
PL
Poland
Prior art keywords
metered dose
dose inhalers
pharmaceutical solution
solution formulations
pressurised metered
Prior art date
Application number
PL07724357T
Other languages
English (en)
Inventor
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38230023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2010190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PL2010190T3 publication Critical patent/PL2010190T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07724357T 2006-04-21 2007-04-19 Formulacje roztworu farmaceutycznego do inhalatorów ciśnieniowych z dozownikiem PL2010190T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
PCT/EP2007/003420 WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
EP07724357.4A EP2010190B1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (1)

Publication Number Publication Date
PL2010190T3 true PL2010190T3 (pl) 2013-11-29

Family

ID=38230023

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07724357T PL2010190T3 (pl) 2006-04-21 2007-04-19 Formulacje roztworu farmaceutycznego do inhalatorów ciśnieniowych z dozownikiem

Country Status (21)

Country Link
US (4) US20060257324A1 (pl)
EP (1) EP2010190B1 (pl)
JP (1) JP5289306B2 (pl)
KR (1) KR101311662B1 (pl)
CN (4) CN105963249A (pl)
AU (1) AU2007241336C1 (pl)
BR (1) BRPI0709510A2 (pl)
CA (1) CA2649556C (pl)
CY (1) CY1114215T1 (pl)
DK (1) DK2010190T3 (pl)
EA (1) EA016262B1 (pl)
ES (1) ES2424753T3 (pl)
HR (1) HRP20130835T1 (pl)
ME (1) ME02342B (pl)
MX (1) MX2008013460A (pl)
PL (1) PL2010190T3 (pl)
PT (1) PT2010190E (pl)
RS (1) RS52940B (pl)
SI (1) SI2010190T1 (pl)
WO (1) WO2007121913A2 (pl)
ZA (1) ZA200808965B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
BRPI0510852A (pt) * 2004-05-13 2007-11-27 Chiesi Farma Spa produtos medicinais em formulação aerossol com estabilidade quìmica aprimorada
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2010138158A1 (en) * 2009-05-15 2010-12-02 Map Pharmaceuticals, Inc. Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
EP2515855B3 (en) * 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
KR20120106753A (ko) * 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
HRP20141240T1 (en) * 2010-02-16 2015-03-13 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable pharmaceutical composition
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
CN102266560A (zh) * 2010-06-04 2011-12-07 北京阜康仁生物制药科技有限公司 一种用于治疗气喘的药物组合物
CN103096897A (zh) * 2010-07-16 2013-05-08 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
RS57687B1 (sr) 2013-12-30 2018-11-30 Chiesi Farm Spa Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition
ES2796177T5 (es) * 2015-12-04 2024-10-29 Mexichem Fluor Sa De Cv Composición farmacéutica
CN109715160A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
WO2018051133A1 (en) 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
MX2019003103A (es) * 2016-09-19 2019-08-01 Mexichem Fluor Sa De Cv Composicion farmaceutica.
CN114712337A (zh) * 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
GEP20217239B (en) 2016-09-19 2021-03-25 Mexichem Fluor Sa De Cv Pharmaceutical composition
AU2019282562A1 (en) 2018-06-04 2021-01-21 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
IL295269A (en) * 2020-02-20 2022-10-01 Chiesi Farm Spa Inhalers with a measured dose under pressure that include the composition of pharmacy buffers
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
EP4221707A4 (en) 2020-09-29 2024-08-28 Aerorx Therapeutics LLC Liquid formulations of indacaterol
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations
WO2026006658A1 (en) 2024-06-27 2026-01-02 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246046A (en) 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US5483953A (en) * 1995-04-08 1996-01-16 The United States Of America As Represented By The Secretary Of The Navy Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ES2234266T3 (es) * 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
JP4672143B2 (ja) * 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
AU2206801A (en) 1999-12-24 2001-07-09 Alan Leslie Cripps Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6451287B1 (en) * 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
ES2342463T3 (es) * 2002-03-01 2010-07-07 Chiesi Farmaceutici S.P.A. Formulacion superfina de formoterol.
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
AU2004264941B2 (en) * 2003-08-11 2008-11-27 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
WO2005077339A1 (en) * 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
KR20070112164A (ko) * 2005-02-15 2007-11-22 엘란 파마 인터내셔널 리미티드 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
AU2007241336C1 (en) 2023-06-29
US20060257324A1 (en) 2006-11-16
BRPI0709510A2 (pt) 2011-07-19
ZA200808965B (en) 2009-12-30
CA2649556C (en) 2014-04-15
EA016262B1 (ru) 2012-03-30
US20090130026A1 (en) 2009-05-21
WO2007121913A2 (en) 2007-11-01
CN105963249A (zh) 2016-09-28
CN102908308A (zh) 2013-02-06
US20200085729A1 (en) 2020-03-19
HRP20130835T1 (hr) 2013-10-25
EP2010190A2 (en) 2009-01-07
JP2009534333A (ja) 2009-09-24
EA200802012A1 (ru) 2009-04-28
CY1114215T1 (el) 2016-08-31
CA2649556A1 (en) 2007-11-01
RS52940B (sr) 2014-02-28
AU2007241336A1 (en) 2007-11-01
PT2010190E (pt) 2013-08-26
AU2007241336B2 (en) 2012-12-06
DK2010190T3 (da) 2013-08-26
JP5289306B2 (ja) 2013-09-11
ME02342B (me) 2016-06-20
CN101389341A (zh) 2009-03-18
MX2008013460A (es) 2008-10-29
ES2424753T3 (es) 2013-10-08
KR20080110985A (ko) 2008-12-22
SI2010190T1 (sl) 2013-10-30
US20170065518A1 (en) 2017-03-09
EP2010190B1 (en) 2013-06-12
US10525006B2 (en) 2020-01-07
US11213485B2 (en) 2022-01-04
CN106074359A (zh) 2016-11-09
KR101311662B1 (ko) 2013-09-25
WO2007121913A3 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
ZA200808965B (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
IL187209A0 (en) Dose counter for metered dose inhalers
EG26133A (en) Inhalation method for measured dosage
GB2441053B (en) Drug capsules for dry powder inhalers
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
GB0614621D0 (en) Metered dose dispensers
PL2058020T3 (pl) Urządzenie do podawania leków
GB0703507D0 (en) Solid pharmaceutical dose
IL193727A0 (en) Dosage forms for administering combinations of drugs
EP1888155A4 (en) DOSE COUNTER FOR INHALER
HUE066059T2 (hu) Dóziseltérést kijelzõ egységgel rendelkezõ adagolóeszköz
ZA200909196B (en) Metered dose inhaler actuator
IL185889A0 (en) Dispenser for delivering medicament
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
GB0921982D0 (en) Metered dose inhaler comprising a dose counter
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
ZA200908962B (en) A liquid formulation for administering nicotine
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
ZA200807348B (en) Dosage aerosols for the administration of pharmaceutical preparations
BRPI0507225A2 (pt) formulações estáveis de solução farmacêutica para inaladores pressurizados de dose medida
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
ZA200706870B (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
ZA201101206B (en) Metered dose inhaler
IL198160A0 (en) Pharmaceutical formulations
IL177103A0 (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers